Drug Trial Radar · NCT05946642
Innovative Intermittent Preventive Treatment Approaches to Reduce Malaria Burden in School-age Children in Burkina Faso
Last checked: Nov 20, 2026Latest source record: Nov 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
13,000
Planned (sponsor's estimate)
Start
Jul 15, 2023
Primary completion
May 31, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- Malaria ConsortiumAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 5 years, up to 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This will be an open label cluster randomized study with two active intervention and one control arm. A cluster will be defined as a selected village. One district implementing seasonal malaria chemoprevention (SMC) will be selected, and six villages will be randomly selected in this district. These six villages will be randomly allocated to each of the three study arms; 1) Arm 1 will receive IPTsc with sulphadoxine-pyrimethamine plus amodiaquine (SPAQ); and 2) Arm 2 will receive dihydroartemisinin-piperaquine (DP) plus Ivermectin (IVM), all given monthly during the transmission season and 3) Control Arm which will have standard malaria control measures including case management and vector control measures as applicable.
Conditions
- Malaria
Interventions
Sulphadoxine-Pyrimethamine/AmodiaquineDrug
Co-blister packaging of sulfadoxine-pyrimethamine (SP) dispersible tablets administered on the first day and amodiaquine (AQ) dispersible tablets administered once daily for three days. The dose of SPAQ will be determined according to the child's age.
Dihydroartemisinin/Piperaquine (DP) plus Ivermectin (IVM)Drug
DP will consist of tablets containing 320/40 mg and 160/20 mg piperaquine/dihydroartemisinin per tablet. A full course of DP should be administered in accordance with the manufacturer's instructions, once a day for 3 days, according to body weight. DP should be taken orally with water and without food. It will be given in association with Ivermectin. Ivermectin (IVM) will be available as 3 mg or 6 mg tablets to be administered at the doses of 300- 400μg/kg/day for 3 days (to the nearest whole tablet). IVM should also be taken with water on an empty stomach.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Prevalence of symptomatic malaria in children of the target age group by microscopy and molecular methods.Time frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Malaria Consortium
Ouagadougou, Burkina Faso · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.